The BET inhibitor JQ1, which binds preferentially to the bromodomains of BRD4, abrogates the expression of the alternative RTK (HER3 and AXL), resulting in significantly delayed acquired resistance in two PDX models of HNSCC (148). Here, AXL is linked to head and neck squamous cell carcinoma.